Overview
- An FDA advisory panel voted that Galleri’s benefits outweigh its risks on Sept. 23, advancing the test toward possible authorization while the agency has not announced a final decision date.
- Two high-profile studies published the day before showed mixed results: PATHFINDER2 found Galleri increased screen-detected cancers and had a high rate of positive results tied to cancer, while the randomized NHS-Galleri trial did not lower combined late-stage (stage 3–4) cancer incidence.
- Galleri detects tumor-derived signals in blood with very high specificity but modest short-term sensitivity, so a positive test requires follow-up imaging or biopsy and is not a diagnosis.
- The test is already sold by prescription for adults 50 and older at about $949, and a 2026 law lets Medicare consider covering FDA-approved multi-cancer tests beginning in 2029, which could sharply expand access and follow-up demand.
- Researchers and regulators plan broad postapproval studies, including NCI’s Vanguard effort, to track longer-term outcomes and whether earlier detection from these tests ultimately reduces cancer deaths.